Abstract 2752
Background
The tumor immune microenvironment (TIME) may hold critical information for developing and optimizing immuno-therapeutic approaches, identifying predictive signatures, and selecting the most adequate treatment option for a given patient. Tissue phenomics facilitates the use of the TIME to derive predictive conclusions. The visual information content in histological sections is systematically converted into numerical readouts using artificial intelligence (AI). Resulting quantitative descriptors, phenes, of detected structures are mined to yield local expression profiles; this spatial data aggregation detects categories of local environments, which are correlated to clinical, genomic or other -omics data to identify relevant cohort subpopulations.
Methods
Exploration of this technology is illustrated by various examples on different cohorts of NSCLC patients: A categorization of n = 45 non-IO-treated patients with respect to local immune profiles learned via AI in a hypothesis-free scenario was examined. A deep learning based PD-L1 scoring was compared to 3 pathologist’s scoring on n = 40 durvalumab-treated patients using the cutoff 25% of tumor cells staining positive for PD-L1 at any intensity. The predictive value of a digital signature combining cell densities of PD-L1 and CD8+ was tested on n = 163 durvalumab-treated and n = 199 non-IO-treated samples.
Results
A categorization into biologically interpretable classes learned by AI illustrates the exploratory benefits of tissue phenomics. The scoring algorithm could reproduce survival prediction when compared to pathologist’s visual scoring.The digital signature suggests a predictive value for patient stratification into responders and non-responders for durvalumab, while no prognostic value could be found on the non-IO-treated patients. Kaplan-Meier plots for the 2 latter examples will be presented in the poster.
Conclusions
Tissue phenomics facilitates the quantitative assessment of the tumor geography and may lead to improved tools for biomarker analysis and diagnosis. Analysis on larger and prospective datasets are to be conducted in the future to strengthen the findings.
Clinical trial identification
All of these results have been generated retrospectively from samples unrelated to a trial or related to the durvalumab-trial NCT01693562.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Boehringer Ingelheim, MedImmune, Definiens AG.
Disclosure
M. Groher: Full / Part-time employment: Definiens AG. J. Zimmermann: Shareholder / Stockholder / Stock options: AstraZeneca; Full / Part-time employment: Definiens AG. H. Musa: Full / Part-time employment: Boehringer Ingelheim. A. Ackermann: Full / Part-time employment: Boehringer Ingelheim. M. Surace: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. J. Rodriguez-Canales: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. M. Rebelatto: Shareholder / Stackeholder / Stock options: AstraZenec LLC; Full / Part-time employment: AstraZeneca LLC. K. Steele: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca; Spouse / Financial dependant: Arcellx LLC. A. Kapil: Full / Part-time employment: Definiens AG. N. Brieu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Definiens AG. L. Rognoni: Full / Part-time employment: Definiens AG. F. Segerer: Full / Part-time employment: Definiens AG. A. Spitzmüller: Full / Part-time employment: Definiens AG. T. Tan: Full / Part-time employment: Definiens AG. A. Schäpe: Full / Part-time employment: Definiens AG. G. Schmidt: Full / Part-time employment: Definiens AG; Shareholder / Stockholder / Stock options: AstraZeneca.
Resources from the same session
3290 - Identification of meningioma patients in high risk of tumor recurrence using microRNA profiling
Presenter: Josef Srovnal
Session: Poster Display session 3
Resources:
Abstract
2477 - Antecedent of cancer and mortality after the first ST segment elevation acute myocardial infarction treated with primary coronary angioplasty. A prospective cohort study
Presenter: Irene Sillero
Session: Poster Display session 3
Resources:
Abstract
1894 - Genomic characterisation of locally advanced pancreatic adenocarcinoma
Presenter: Sarah Picardo
Session: Poster Display session 3
Resources:
Abstract
3280 - Comparison of freshly prepared and frozen cells from colorectal cancer surgical samples for phenotyping experiments- a pilot study
Presenter: Sandra Mersakova
Session: Poster Display session 3
Resources:
Abstract
3419 - Hyaluronan (HA) Accumulation in the Tumor Microenvironment (TME) is Increased in Colorectal Cancer (CRC) and Associated with Consensus Molecular Subtypes (CMS) 4 Molecular Subtype
Presenter: Barbara Blouw
Session: Poster Display session 3
Resources:
Abstract
1833 - Evaluation of CT-based radiomics in patients with renal cell carcinoma
Presenter: An Zhao
Session: Poster Display session 3
Resources:
Abstract
5883 - Detection of Double Protein Expression in Diffuse Large B Cell Lymphoma
Presenter: Mohamed Gouda
Session: Poster Display session 3
Resources:
Abstract
5415 - Encyclopedic Tumor Analysis for organ agnostic treatment with Axitinib in combination regimens for advanced cancers
Presenter: Tim Crook
Session: Poster Display session 3
Resources:
Abstract
3297 - Computational model to predict response rate of clinical trials
Presenter: Orsolya Lorincz
Session: Poster Display session 3
Resources:
Abstract
4355 - Analysis of BRCA genes and homologous recombination deficiency (HRD) scores in tumours from patients (pts) with metastatic breast cancer (mBC) in the OlympiAD trial
Presenter: Mark Robson
Session: Poster Display session 3
Resources:
Abstract